Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Aug 7;4(F1000 Faculty Rev):517.
doi: 10.12688/f1000research.6378.1. eCollection 2015.

Novel Insights and Therapeutics in Multiple Sclerosis

Catriona A Wagner  1 , Joan M Goverman  1
Affiliations
Review

Novel Insights and Therapeutics in Multiple Sclerosis

Catriona A Wagner et al. F1000Res. .

Abstract

The last twelve years have witnessed the development of new therapies for relapsing-remitting multiple sclerosis that demonstrate increased efficacy relative to previous therapies. Many of these new drugs target the inflammatory phase of disease by manipulating different aspects of the immune system. While these new treatments are promising, the development of therapies for patients with progressive multiple sclerosis remains a significant challenge. We discuss the distinct mechanisms that may contribute to these two types of multiple sclerosis and the implications of these differences in the development of new therapeutic targets for this debilitating disease.

Keywords: immune; multiple sclerosis; therapeutics.

PubMed Disclaimer

Conflict of interest statement

Competing interests: No competing interests were disclosed.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. International Multiple Sclerosis Genetics Consortium, . Hafler DA, Compston A, et al. : Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med. 2007;357(9):851–862. 10.1056/NEJMoa073493 - DOI - PubMed

    2. F1000 Recommendation

    1. International Multiple Sclerosis Genetics Consortium, . Wellcome Trust Case Control Consortium, . Sawcer S, et al. : Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011;476(7359):214–219. 10.1038/nature10251 - DOI - PMC - PubMed

    2. F1000 Recommendation

    1. Brynedal B, Duvefelt K, Jonasdottir G, et al. : HLA-A confers an HLA-DRB1 independent influence on the risk of multiple sclerosis. PLoS One. 2007;2(7):e664. 10.1371/journal.pone.0000664 - DOI - PMC - PubMed

    2. F1000 Recommendation

    1. Goverman J: Autoimmune T cell responses in the central nervous system. Nat Rev Immunol. 2009;9(6):393–407. 10.1038/nri2550 - DOI - PMC - PubMed
    1. Aktas O, Kieseier B, Hartung HP: Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis. Trends Neurosci. 2010;33(3):140–152. 10.1016/j.tins.2009.12.002 - DOI - PubMed

    2. F1000 Recommendation